Literature DB >> 31671379

Stimulation of 5-HT2C serotonin receptor subtype in the hypothalamic arcuate nuclei (ARC) increases the cytochrome P450 activity in the liver.

Ewa Bromek1, Marta Rysz1, Anna Haduch1, Władysława A Daniel2.   

Abstract

BACKGROUND: Our previous study has demonstrated that activation of the 5-HT2, but not 5-HT1 serotonin receptor type in the hypothalamic arcuate nucleus (ARC) is responsible for the neuroendocrine regulation of liver cytochrome P450. The goal of these studies was to determine whether 5-HT2C serotonin receptor subtype in the ARC is engaged in the regulation of liver cytochrome P450.
METHODS: The 5-HT2C serotonin receptor agonist CP-809,101 was injected into the ARC for 5 days. The liver cytochrome P450 activity and protein level were measured.
RESULTS: In rats receiving an injection of the 5-HT2C serotonin receptor agonist CP-809,101 into the ARC (1 μg/side) for five days, the activities of CYP2B, CYP2C11 and CYP3A significantly increased corresponding with the elevated enzyme protein level.
CONCLUSIONS: The obtained results suggest that the 5-HT2C serotonin receptor subtype in the ARC is involved in the positive neuroendocrine regulation of cytochrome P450. Further studies are in progress to explain the physiological mechanism which is responsible for the observed regulation of cytochrome P450 by 5-HT2C receptor present in the ARC.
Copyright © 2019 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-HT(2C) serotonin receptor; Cytochrome P450; Hypothalamic arcuate nucleus

Mesh:

Substances:

Year:  2019        PMID: 31671379     DOI: 10.1016/j.pharep.2019.05.010

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  1 in total

1.  The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat.

Authors:  Anna Haduch; Ewa Bromek; Marta Rysz; Renata Pukło; Mariusz Papp; Piotr Gruca; Magdalena Łasoń; Monika Niemczyk; Władysława A Daniel
Journal:  Pharmacol Rep       Date:  2020-08-03       Impact factor: 3.024

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.